heapsreal
iherb 10% discount code OPA989,
- Messages
- 10,227
- Location
- australia (brisbane)
In one study that focused on men, scientists proposed that the oral administration of DHEA to elderly men would result in activation of their immune system: nine healthy men averaging 63 years of age were treated with a placebo for two weeks followed by 20 weeks of DHEA (50 mg a day). After two weeks on oral DHEA, serum DHEA levels increased by 3-4 times. These levels were sustained throughout the study. Compared to the placebo, DHEA administration resulted in: An increase of 20% in IGF-1. Many people are taking expensive growth hormone injections for the purpose of boosting IGF (insulin-like growth factor) levels. IGF is thought to be responsible for some of the antiaging, anabolic effects that DHEA has produced in previous human studies.
An increase of 35% in the number of monocyte immune cells.
An increase of 29% in the number of B immune cells and a 62% increase in B-cell activity.
A 40% increase in T-cell activity even though the total number of T-cells was not affected.
An increase of 50% in interleukin-2.
An increase of 22-37% in natural killer cell (NK) numbers and an increase of 45% in NK cell activity.
No adverse effects were noted with DHEA administration.
A study published in the Journal of Clinical Endocrine Metabolism showed that when old female mice were treated with DHEA, melatonin, or DHEA and melatonin, splenocytes (macrophages) were significantly higher as compared to young mice. B-cell proliferation in young and in old mice significantly increased. DHEA, melatonin, and DHEA and melatonin helped to regulate immune function in aged female mice by significantly increasing the cytokines interleukin-2 and interferon-gamma and significantly decreasing the cytokines interleukin-6 and interleukin-10, thus regulating cytokine production (Inserra et al. 1998).
Interleukin-6 (IL-6) is one of the pathogenic elements in inflammatory and age-related diseases, such as rheumatoid arthritis, osteoporosis, atherosclerosis, and late-onset B-cell neoplasia. According to a report in the June 1999 issue of the Journal of the American Geriatrics Society , "higher circulating levels of IL-6 predict disability onset in older persons." The authors suggest that IL-6 may cause a reduction in muscle strength or contribute to specific diseases such as congestive heart failure, osteoporosis, arthritis, and dementia, which cause disability (Ferrucci et al. 1999).
DHEA has consistently been shown to boost beneficial interleukin-2 and suppress damaging interleukin-6 (IL-6) levels. Interleukin-6 is overproduced in the aged, which contributes to autoimmune disease, immune dysfunction, osteoporosis, depressions in healing, breast cancer, B-cell lymphoma, and anemia. Continuous DHEA administration maintained immunocompetence in aged animals (by boosting interleukin-2 and other beneficial immune components and suppressing interleukin-6 and other detrimental immune components). Suppression of interleukin-6 with 200 mg a day of DHEA was shown to be effective against systemic lupus erythematosus (Van Vollenhoven et al. 1998).
http://www.lifeextensionvitamins.com/dhrethpa2.html
An increase of 35% in the number of monocyte immune cells.
An increase of 29% in the number of B immune cells and a 62% increase in B-cell activity.
A 40% increase in T-cell activity even though the total number of T-cells was not affected.
An increase of 50% in interleukin-2.
An increase of 22-37% in natural killer cell (NK) numbers and an increase of 45% in NK cell activity.
No adverse effects were noted with DHEA administration.
A study published in the Journal of Clinical Endocrine Metabolism showed that when old female mice were treated with DHEA, melatonin, or DHEA and melatonin, splenocytes (macrophages) were significantly higher as compared to young mice. B-cell proliferation in young and in old mice significantly increased. DHEA, melatonin, and DHEA and melatonin helped to regulate immune function in aged female mice by significantly increasing the cytokines interleukin-2 and interferon-gamma and significantly decreasing the cytokines interleukin-6 and interleukin-10, thus regulating cytokine production (Inserra et al. 1998).
Interleukin-6 (IL-6) is one of the pathogenic elements in inflammatory and age-related diseases, such as rheumatoid arthritis, osteoporosis, atherosclerosis, and late-onset B-cell neoplasia. According to a report in the June 1999 issue of the Journal of the American Geriatrics Society , "higher circulating levels of IL-6 predict disability onset in older persons." The authors suggest that IL-6 may cause a reduction in muscle strength or contribute to specific diseases such as congestive heart failure, osteoporosis, arthritis, and dementia, which cause disability (Ferrucci et al. 1999).
DHEA has consistently been shown to boost beneficial interleukin-2 and suppress damaging interleukin-6 (IL-6) levels. Interleukin-6 is overproduced in the aged, which contributes to autoimmune disease, immune dysfunction, osteoporosis, depressions in healing, breast cancer, B-cell lymphoma, and anemia. Continuous DHEA administration maintained immunocompetence in aged animals (by boosting interleukin-2 and other beneficial immune components and suppressing interleukin-6 and other detrimental immune components). Suppression of interleukin-6 with 200 mg a day of DHEA was shown to be effective against systemic lupus erythematosus (Van Vollenhoven et al. 1998).
http://www.lifeextensionvitamins.com/dhrethpa2.html